Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8327566 | 0.86 | KIF11 (0.56) | KIF11TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL1857632 | 0.86 | KIF11 (0.56) | KIF11TSHRCYP1A2MAPK1 | |
| SCHEMBL9852930 | 0.78 | SMN1; SMN2 (0.47) | CYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL532102 | 0.78 | KIF11 (0.54) | KIF11KCNN4TSHRALDH1A1CYP11B1 | |
| SCHEMBL6695096 | 0.76 | SMN1; SMN2 (0.45) | KIF11TSHRCYP11B1CYP11B2CYP1A2 | |
| SCHEMBL1149158 | 0.75 | KIF11 (0.64) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL28873040 | 0.75 | KIF11 (0.50) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL20534911 | 0.74 | CYP2C19 (0.46) | KCNN4TSHRALDH1A1TAAR1CYP1A2 | |
| SCHEMBL7814535 | 0.74 | KCNN4 (0.46) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL3077118 | 0.74 | KIF11 (0.61) | KIF11CYP11B1CYP11B2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114599753-A | Polishing composition and method with high selectivity for silicon nitride and polysilicon versus silicon oxide | CMC材料股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-20120288752-A1 | ADDITIVE FOR OVERCHARGE PREVENTING OF SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY INCLUDING THE SAME | SAMSUNG CORNING PRECISION MATERIALS CO., LTD. | 2012-11-15 | — | — | US | claimed |
| EP-2523247-A1 | Additive for overcharge preventing of secondary battery and non-aqueous electrolyte for secondary battery including the same | Samsung Corning Precision Materials Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | claimed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| CN-118103209-A | Composition for forming release layer, laminate, and method for producing laminate | 日产化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-4371984-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-0024091-B1 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
| EP-0071281-A2 | Hydroformylation process | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-02-09 | — | — | EP | disclosed |
| EP-0024091-A4 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS. | EXXON RESEARCH ENGINEERING CO (US) | 1981-07-16 | — | — | EP | disclosed |
| EP-0024091-A1 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS. | EXXON RESEARCH ENGINEERING CO (US) | 1981-02-25 | — | — | EP | disclosed |
| WO-1980001690-A1 | CARBONYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS | EXXON RESEARCH ENGINEERING CO (US) | 1980-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | KIF11 2391/4885KCNN4 4778/4885TSHR 2993/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | KIF11 1583/4885KCNN4 4605/4885TSHR 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.